Clinical Trial Update: Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET [Phase 2]

View source ↗

Summary

Phase II study investigating everolimus combined with octreotide LAR for advanced gastrointestinal neuroendocrine tumors has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neoplasms

Drugs mentioned

• Everolimus (everolimus)
• Octreotide LAR (octreotide long-acting release)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Gastrointestinal Neoplasms | Phase 2 | Status: COMPLETED